A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma

Most ovarian cancer patients are diagnosed at a late stage with 85% of them relapsing after surgery and standard chemotherapy; for this reason, new treatments are urgently needed. Ovarian cancer has become a c...

Source: Journal of Translational Medicine - November 26, 2019 Category: Research Authors: Apostolos Sarivalasis, Caroline Boudousqui é, Klara Balint, Brian J. Stevenson, Philippe O. Gannon, Emanuela Marina Iancu, Laetitia Rossier, Silvia Martin Lluesma, Patrice Mathevet, Christine Sempoux, George Coukos, Urania Dafni, Alexandre Harari, Michal Tags: Protocol Source Type: research